?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical ?d T cell immunotherapy landscape. In five chapters, field experts discuss the challenges facing ?d T cell oncoimmunotherapy, propose solutions, and map next steps. Particular attention is given to summarizing our understanding of the complex, translationally relevant human ?d T cell biology, the evidence basis for designing ?d T cell combination trials and data-driven perspectives on what is known—and what isn’t—about ?d T cell therapeutic persistence.Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering. A chapter is dedicated to the systematic review of all ?d T cell immunotherapy trials to date, and the cell therapy products that were used in these trials.The final chapter discusses allograft persistence-enhancement techniques in the context of ?d T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering. ?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of ?dT cell immunotherapy, which is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.